After HCT, pharmacological inhibition of CerS6 with ST1072 reduces the numbers of IFN-γ-producing and total human T cells in secondary lymphoid and GVHD target organs in a xeno-GVHD model (41). The gene discussed is CERS6; the disease is graft versus host disease.